发明名称 |
TARGETED FUSION PROTEINS FOR CANCER THERAPY |
摘要 |
<p>The invention relates to fusion proteins useful as therapeutics against cancer. The fusion protein comprises of cell-targeting moiety and apoptosis-inducing moiety. Cell-targeting moiety and apoptosis-inducing moiety are linked by a flexible linker, which are specifically recognized by cancer specific protease and cleaved in situ to release the apoptotic domain. In particular, the invention is illustrated by a recombinant fusion protein between human Vasoactive Intestinal Peptide (VIP) and BH3 domain of Bcl2 family protein, linked by a linker that has site for cancer specific proteases. The fusion protein specifically targets VIP receptor over-expressing cancer cells and induces cell-specific apoptosis after cleavage at the linker site by cancer specific proteases. Such fusion proteins are useful for the delivery of therapeutic/apoptotic moiety (peptides) to specific cells with perturbed expression of, but not limited to neuropeptide receptors.</p> |
申请公布号 |
EP1957524(B1) |
申请公布日期 |
2010.02.17 |
申请号 |
EP20060821700 |
申请日期 |
2006.11.16 |
申请人 |
DABUR PHARMA LIMITED |
发明人 |
MAITHAL, KAPIL;NACHIAPPAN, DHATCHANA, MOORTHY;MUKHERJEE, RAMA |
分类号 |
C07K14/435;A61K38/17 |
主分类号 |
C07K14/435 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|